Recent Updates
Recently added Catalysts
AMGN

Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018, in London....

Key Takeaway: THOUSAND OAKS, Calif. , Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018 , in London . David W. Meline , executive vice president and chief financial officer

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Maridebart cafraglutide
Phase 3 · Heart Failure With Preserved Ejection Fraction

Full Press Release Details

THOUSAND OAKS, Calif. , Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018 , in London . David W. Meline , executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com , under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Last updated: Sep 11, 2018